Building A US Business: Celltrion’s New CCO Talks Strategy
Biosimilars Specialist Moves To Direct Sales Model In US With Three Key Launches
Executive Summary
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks about how the firm is gearing up to launch three key products.
You may also be interested in...
Who's Hired? Padagis Gets New Leadership
Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.
Amgen Talks Dual Pricing Strategy For Amjevita
In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.
AAM Sees Boon From Biden Order And CMS Biosimilar Action
The US Association for Accessible Medicines has welcomed an executive order from president Joe Biden aimed at lowering prescription drug costs, shortly after the AAM’s Biosimilars Council praised payment changes for biosimilars made by the Centers for Medicare & Medicaid Services.